Research ExplorerPublicationsPSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic ca...

PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression

Standard

PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. / Sahni, Sumit; Krisp, Christoph; Molloy, Mark P; Nahm, Christopher; Maloney, Sarah; Gillson, Josef; Gill, Anthony J; Samra, Jaswinder; Mittal, Anubhav.

In: BBA-GEN SUBJECTS, Vol. 1864, No. 11, 11.2020, p. 129682.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sahni, S, Krisp, C, Molloy, MP, Nahm, C, Maloney, S, Gillson, J, Gill, AJ, Samra, J & Mittal, A 2020, 'PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression', BBA-GEN SUBJECTS, vol. 1864, no. 11, pp. 129682. https://doi.org/10.1016/j.bbagen.2020.129682

APA

Sahni, S., Krisp, C., Molloy, M. P., Nahm, C., Maloney, S., Gillson, J., Gill, A. J., Samra, J., & Mittal, A. (2020). PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. BBA-GEN SUBJECTS, 1864(11), 129682. https://doi.org/10.1016/j.bbagen.2020.129682

Vancouver

Sahni S, Krisp C, Molloy MP, Nahm C, Maloney S, Gillson J et al. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. BBA-GEN SUBJECTS. 2020 Nov;1864(11):129682. https://doi.org/10.1016/j.bbagen.2020.129682

Bibtex

@article{6b1362f061e844129b78162bd4b6fece,
title = "PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression",
abstract = "BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Surgery is the only curative intent therapy, but the majority of patients experience disease relapse. Thus, patients who do not benefit from highly morbid surgical resection needs to be identified and offered palliative chemotherapy instead. In this pilot study, we aimed to identify differentially regulated proteins in plasma and plasma derived microparticles from PDAC patients with poor and good prognosis.METHODS: Plasma and plasma derived microparticle samples were obtained before surgical resection from PDAC patients. Sequential Windowed Acquisition of all Theoretical fragment ion spectra - Mass Spectrometry (SWATH-MS) proteomic analysis was performed to identify and quantify proteins in these samples. Statistical analysis was performed to identify biomarkers for poor prognosis.RESULTS: A total of 482 and 1024 proteins were identified from plasma and microparticle samples, respectively, by SWATH-MS analysis. Statistical analysis of the data further identified nine and six differentially (log2ratio > 1, p < .05) expressed proteins in plasma and microparticles, respectively. Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis.CONCLUSION AND GENERAL SIGNIFICANCE: A novel blood-based biomarker signature for PDAC prognosis was identified.",
author = "Sumit Sahni and Christoph Krisp and Molloy, {Mark P} and Christopher Nahm and Sarah Maloney and Josef Gillson and Gill, {Anthony J} and Jaswinder Samra and Anubhav Mittal",
note = "Copyright {\textcopyright} 2020 Elsevier B.V. All rights reserved.",
year = "2020",
month = nov,
doi = "10.1016/j.bbagen.2020.129682",
language = "English",
volume = "1864",
pages = "129682",
journal = "BBA-GEN SUBJECTS",
issn = "0304-4165",
publisher = "Elsevier",
number = "11",

}

RIS

TY - JOUR

T1 - PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression

AU - Sahni, Sumit

AU - Krisp, Christoph

AU - Molloy, Mark P

AU - Nahm, Christopher

AU - Maloney, Sarah

AU - Gillson, Josef

AU - Gill, Anthony J

AU - Samra, Jaswinder

AU - Mittal, Anubhav

N1 - Copyright © 2020 Elsevier B.V. All rights reserved.

PY - 2020/11

Y1 - 2020/11

N2 - BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Surgery is the only curative intent therapy, but the majority of patients experience disease relapse. Thus, patients who do not benefit from highly morbid surgical resection needs to be identified and offered palliative chemotherapy instead. In this pilot study, we aimed to identify differentially regulated proteins in plasma and plasma derived microparticles from PDAC patients with poor and good prognosis.METHODS: Plasma and plasma derived microparticle samples were obtained before surgical resection from PDAC patients. Sequential Windowed Acquisition of all Theoretical fragment ion spectra - Mass Spectrometry (SWATH-MS) proteomic analysis was performed to identify and quantify proteins in these samples. Statistical analysis was performed to identify biomarkers for poor prognosis.RESULTS: A total of 482 and 1024 proteins were identified from plasma and microparticle samples, respectively, by SWATH-MS analysis. Statistical analysis of the data further identified nine and six differentially (log2ratio > 1, p < .05) expressed proteins in plasma and microparticles, respectively. Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis.CONCLUSION AND GENERAL SIGNIFICANCE: A novel blood-based biomarker signature for PDAC prognosis was identified.

AB - BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Surgery is the only curative intent therapy, but the majority of patients experience disease relapse. Thus, patients who do not benefit from highly morbid surgical resection needs to be identified and offered palliative chemotherapy instead. In this pilot study, we aimed to identify differentially regulated proteins in plasma and plasma derived microparticles from PDAC patients with poor and good prognosis.METHODS: Plasma and plasma derived microparticle samples were obtained before surgical resection from PDAC patients. Sequential Windowed Acquisition of all Theoretical fragment ion spectra - Mass Spectrometry (SWATH-MS) proteomic analysis was performed to identify and quantify proteins in these samples. Statistical analysis was performed to identify biomarkers for poor prognosis.RESULTS: A total of 482 and 1024 proteins were identified from plasma and microparticle samples, respectively, by SWATH-MS analysis. Statistical analysis of the data further identified nine and six differentially (log2ratio > 1, p < .05) expressed proteins in plasma and microparticles, respectively. Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis.CONCLUSION AND GENERAL SIGNIFICANCE: A novel blood-based biomarker signature for PDAC prognosis was identified.

U2 - 10.1016/j.bbagen.2020.129682

DO - 10.1016/j.bbagen.2020.129682

M3 - SCORING: Journal article

C2 - 32663515

VL - 1864

SP - 129682

JO - BBA-GEN SUBJECTS

JF - BBA-GEN SUBJECTS

SN - 0304-4165

IS - 11

ER -